SCHEMBL2352150

SCHEMBL2352150

CC(C)(OCc1ccc(I)cc1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.46
▸ RXRB P28702 1/20 0.46
▸ PPARG P37231 5/20 0.45
▸ PPARA Q07869 5/20 0.45
▸ APP P05067 5/20 0.44
▸ SLC16A3 O15427 3/20 0.43
▸ SLC16A1 P53985 1/20 0.43
▸ MCTS1 Q9ULC4 1/20 0.43
▸ CYP3A4 P08684 2/20 0.42
▸ IDO1 P14902 2/20 0.42
▸ PPARD Q03181 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL883026 0.83 SLC16A3 (0.55) PPARGPPARASLC16A3SLC16A1MCTS1
SCHEMBL2716903 0.83 CYP3A4 (0.44) RXRARXRBAPPCYP3A4IDO1
SCHEMBL8935661 0.82 SLC16A3 (0.46) PPARGPPARASLC16A3SLC16A1MCTS1
SCHEMBL2215266 0.82 RXRA (0.46) RXRARXRBPPARGPPARASLC16A3
SCHEMBL31377393 0.81 NPC1 (0.53) PPARGPPARASLC16A3SLC16A1MCTS1
SCHEMBL2221138 0.81 SLC16A3 (0.53) PPARGSLC16A3SLC16A1MCTS1IDO1
SCHEMBL8935846 0.79 PPARA (0.50) PPARGPPARAIDO1PPARD
Clobuzarit SCHEMBL187456 0.78 SLC16A3 (0.62) PPARGPPARASLC16A3SLC16A1MCTS1
SCHEMBL11734564 0.78 PPARG (0.72) RXRARXRBPPARGPPARAAPP
SCHEMBL11957480 0.77 CYP3A4 (0.52) APPCYP3A4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1647546-B1 NOVEL HETEROARYL DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2012-05-02 — — EP disclosed
EP-1647546-B1 NOVEL HETEROARYL DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2012-05-02 — — EP disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 — — US disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 — — US disclosed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 — — US disclosed
EP-2351563-A1 AGENT FOR TREATMENT OF DIABETES Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-08-03 — — EP disclosed
EP-2351563-A1 AGENT FOR TREATMENT OF DIABETES Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-08-03 — — EP disclosed
US-20100286144-A1 HETEROARYL DERIVATIVES TAKAHASHI YOKO 2010-11-11 — — US disclosed
US-20100286144-A1 HETEROARYL DERIVATIVES TAKAHASHI YOKO 2010-11-11 — — US disclosed
US-20100286144-A1 HETEROARYL DERIVATIVES TAKAHASHI YOKO 2010-11-11 — — US disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 — — US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 — — US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 — — US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 — — US disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 — — US disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 — — US disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 — — US disclosed
EP-1837329-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2007-09-26 — — EP disclosed
US-20060194857-A1 Novel heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) 2006-08-31 — — US disclosed
EP-1647546-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-04-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES SLC5A1, GLP1R, SLC5A2 RXRA 1671/4885RXRB 2084/4885PPARG 62/4885
US-20060194857-A1 Novel heteroaryl derivative NR0B1, UGT1A10, NR0B2 RXRA 307/4885RXRB 262/4885PPARG 282/4885
US-20100286144-A1 HETEROARYL DERIVATIVES GPR119, SLC2A1, SLC2A4 RXRA 630/4885RXRB 736/4885PPARG 430/4885
US-20080167306-A1 Novel Heteroaryl Derivative GPR119, SLC2A4, SLC5A2 RXRA 818/4885RXRB 935/4885PPARG 498/4885
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE NR0B1, UGT1A10, NR0B2 RXRA 307/4885RXRB 262/4885PPARG 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback